PitchSend

argenx SE Investor Day Presentation Deck

Efgartigimod Designed to Clear IgG Autoantibodies Regardless of Target Antigen IMNM (70% MSA+) anti-SRP Anti-HMGCR MAA or Abs against unidentified targets argenx ASYS (100% MSA+) anti-Jo-1 anti-PL-12 anti-PL-7 other anti-synthetases DM (75% MSA+) anti-Mi-2 anti-NXP-2 anti-MDA5 anti-TIF-1y anti-SAE MAA or Abs against unidentified targets Defining new myositis biology Myositis patients can have myositis-specific autoantibodies (MSA+), myositis-associated autoantibodies (MAA+) or autoantibodies against yet unknown targets 29

View entire presentation